Bullish indicating open at $55-$60, IPO prices at $37
MONTPELLIER, France - Sensorion (FR0012596468 – ALSEN), a clinical-stage biotech company with a market capitalization of $125.4 million, announced Tuesday it has completed patient enrollment in the second cohort of its Phase 1/2 Audiogene clinical trial evaluating SENS-501, a gene therapy candidate for congenital deafness caused by mutations in the OTOF gene. The company’s stock has shown strong momentum, gaining over 16% in the past week, though InvestingPro analysis suggests the stock is currently undervalued.
The second cohort consists of three patients aged between 6 and 31 months who received a higher dose (4.5E11 vg/vector/ear) of SENS-501 compared to the first cohort (1.5E11 vg/vector/ear). According to the company’s press release statement, the surgical procedure for intra-cochlear administration was well tolerated in all patients from both cohorts, with no serious adverse events reported. While advancing its clinical programs, InvestingPro data shows the company maintains a strong financial position with more cash than debt and a healthy current ratio of 6.28, though it is currently burning through cash rapidly.
The company noted early signs of hearing improvement in one patient from the first cohort, an 11-month-old, observed three months after receiving the lower dose.
The Audiogene trial (ClinicalTrials.gov ID:NCT06370351) is targeting infants and toddlers aged 6 to 31 months who have not received cochlear implants. The clinical trial aims to assess both safety and the therapy’s ability to restore hearing and enable normal speech development.
SENS-501 works by introducing a functional copy of the OTOF gene directly into hair cells of the inner ear using viral vector technology. The gene therapy was developed as part of the RHU AUDINNOVE consortium, which includes Sensorion, Necker Enfants Malades Hospital, Institut Pasteur, and Fondation pour l’Audition.
The OTOF gene was discovered in 1999 at the Institut Pasteur by Professor Christine Petit’s team.
Sensorion plans to hold a Data Monitoring Committee meeting and will provide updates as data matures further. Analysts maintain a bullish outlook on the company, with the next earnings report expected on September 17, 2025. Get access to more detailed financial insights and 7 additional ProTips with InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.